Review Articles

Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era



Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.


COVID-19heart failureheart transplantleft ventricular assist device
  • Year: 2021
  • Volume: 17 Issue: 5
  • Page/Article: 63-72
  • DOI: 10.14797/mdcvj.651
  • Submitted on 31 Aug 2021
  • Accepted on 11 Nov 2021
  • Published on 15 Dec 2021
  • Peer Reviewed